June 13th 2025
Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.
Dr Blase Polite Outlines the Decision to Move to 2-Sided Risk in the OCM
Dr James Hamrick Discusses Bringing Value to Patients Through Engagement
Lessons From the Field: How Practices Are Succeeding Under OCM
Mike Fazio: Practices Are Happier With PP4 Results in the OCM